Navigation Links
Webcast Alert: Cytomedix Inc (GTF) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation
Date:7/15/2010

NEW YORK, July 15 /PRNewswire-FirstCall/ -- Cytomedix Inc (GTF) announces the following Webcast:

What:  LHA Life Sciences & Med Tech Day 2010 Presentation

When:  July 20, 2010 @ 9:00 AM Eastern

Where:  http://www.investorcalendar.com/ClientPage.asp?ID=160316

How:  Live over the Internet -- Simply log on to the web at the address above.

Contact:  Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=160316 or http://www.investorcalendar.com/

Cytomedix, Inc. (NYSE Amex: GTF)  Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, to primarily address the areas of wound care, inflammation, and angiogenesis. The Company currently markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma ("PRP") in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma.  The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also pursuing opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics, as well as actively seeking complementary products for the wound care market. The Company also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing, or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that has shown promise in pre-clinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.


'/>"/>
SOURCE Cytomedix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation
2. Angiotech Pharmaceuticals Announces Conference Call and Webcast
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Caliper Life Sciences to Webcast Investor Session of Open House
5. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
6. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
7. Resverlogix Notice of Conference Call & Webcast for Year End Update
8. Advanced Life Sciences to Host 2010 First Quarter Financial Results Conference Call and Webcast
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Volcano Corporation Schedules First Quarter Conference Call, Webcast
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
Breaking Biology News(10 mins):